Published in

Karger Publishers, Molecular Syndromology, 1(6), p. 32-38, 2015

DOI: 10.1159/000370169

Links

Tools

Export citation

Search in Google Scholar

Clinical and Molecular Heterogeneity in Brazilian Patients with Sotos Syndrome

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Sotos syndrome (SoS) is a multiple anomaly, congenital disorder characterized by overgrowth, macrocephaly, distinctive facial features and variable degree of intellectual disability. Haploinsufficiency of the <i>NSD1</i> gene at 5q35.3, arising from 5q35 microdeletions, point mutations, and partial gene deletions, accounts for a majority of patients with SoS. Recently, mutations and possible pathogenetic rare CNVs, both affecting a few candidate genes for overgrowth, have been reported in patients with Sotos-like overgrowth features. To estimate the frequency of <i>NSD1</i> defects in the Brazilian SoS population and possibly reveal other genes implicated in the etiopathogenesis of this syndrome, we collected a cohort of 21 Brazilian patients, who fulfilled the diagnostic criteria for SoS, and analyzed the <i>NSD1</i> and <i>PTEN</i> genes by means of multiplex ligation-dependent probe amplification and mutational screening analyses. We identified a classical <i>NSD1</i> microdeletion, a novel missense mutation (p.C1593W), and 2 previously reported truncating mutations: p.R1984X and p.V1760Gfs*2. In addition, we identified a novel de novo <i>PTEN</i> gene mutation (p.D312Rfs*2) in a patient with a less severe presentation of SoS phenotype, which did not include pre- and postnatal overgrowth. For the first time, our study implies <i>PTEN</i> in the pathogenesis of SoS and further emphasizes the existence of ethno-geographical differences in <i>NSD1</i> molecular alterations between patients with SoS from Europe/North America (70-93%) and those from South America (10-19%).